matrix metalloproteinase

(redirected from Matrix metalloprotease)
Also found in: Medical.

matrix metalloproteinase

[¦mā·triks mə‚tal·ō′prō·tē·ə‚nās]
(biochemistry)
Any member of a family of at least 19 structurally related zinc-dependent neutral endopeptidases collectively capable of degrading essentially all components of extracellular matrix.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
The results revealed that 37 canonical pathways were enriched within the 99 genes upregulated in diabetic group and subsequently downregulated after HXJD treatment, including the role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis, matrix metalloprotease inhibition, and IL-6 signalling.
Acute venous occlusion enhances matrix metalloprotease activity: implications on endothelial dysfunction.
Patients who improved the most on doxycycline also had the lowest activity of serine protease and matrix metalloprotease (MMP) in their skin, reported Anna Di Nardo, MD, PhD, of the University of California San Diego in La Jolla.
Valle-Garay, "The effect of gender and genetic polymorphisms on matrix metalloprotease (MMP) and tissue inhibitor (TIMP) plasma levels in different infectious and noninfectious conditions," Clinical and Experimental Immunology, vol.
Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration.
Matrix metalloprotease (MMP) is an endopeptidase expressed in human urine whenever cancer is present.
Wu et al., "Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)," Bioorganic & Medicinal Chemistry Letters, vol.
Recently, our laboratory demonstrated that miR-488 contributes to the regulation of matrix metalloprotease (MMP)-2 [13].
Other "targeted therapies" such as matrix metalloprotease inhibitors, inhibitors of angiogenesis, anti-EGFR antibodies or farnesyltransferasein-hibitors failed in large phase III trials.
8:02 Matrix Metalloprotease Activity Is Increased in Obese Dog Kidneys
AG3340, a matrix metalloprotease inhibitor demonstrating potent anti-angiogenic and anti-metastatic properties is in Phase III clinical trials in combination with the anticancer drugs paclitaxcl/carboplatin for the proposed treatment of non-small cell lung cancer, and with mitoxantrone/prednisone for the proposed treatment of hormone-refractory prostate cancer.
Full browser ?